Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.
Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.
For all the importance of the role of government and private sector bodies in the realisation of precision medicine, it’s important not to lose sight of the interests and concerns of those precision medicine intends to treat—the patients and public at large, write Daniel Lim and Anna Jackson of Kirkland & Ellis.
In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.
Precision medicine is an evolving field, which takes individual variability in genes, environment, and lifestyle into account when tackling disease treatment and prevention. LSIPR reports.
3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
An upcoming case on the patent eligibility of genetically modified seed in India will have far-reaching ramifications, as Archana Shankar and Gitika Suri of Anand & Anand explain.